A rallying point for cancer research

AACR’s Annual Meeting 2013 and Rally for Medical Research draw thousands to nation’s capital
| 3 min read
Register for free to listen to this article
Listen with Speechify
0:00
3:00

WASHINGTON, D.C.—More than 18,000 researchers convened inthe nation's capital April 6-10 to participate in the American Association forCancer Research (AACR) Annual Meeting 2013, which featured presentations of thelatest science and most exciting recent discoveries in cancer research.
 
 
This image is no longer available The theme for this year's meeting was "Personalizing CancerCare Through Discovery Science," celebrating the accelerated pace ofdiscoveries in basic, translational and clinical cancer research due in largepart to the availability of new technologies.
 
The meeting took place at the Walter E. WashingtonConvention Center in Washington, D.C., with an exhibit show running April 7-10.
 
Programs included invited talks by a roster of hundreds ofrenowned speakers and more than 6,000 proffered papers from the world's topcancer researchers.
 
 
The programming aimed to cover all aspects of cancerresearch. The program for the Annual Meeting 2013 was organized into topic andorgan site tracks to help attendees to navigate such a comprehensive agenda.
 
 
Exhibits and poster sessions filled the lower level of theconvention center with constant activity. Exhibitors included a range ofcompanies with products and services related to laboratory and clinicalresearch. Special areas of interest on the exhibit floor included a nonprofitsection and an area for research publishers.
 
 
The forum provided a valuable opportunity for members of theworldwide cancer research community to learn, interact, and collaborate withone another. The exhibits and poster sessions in close proximity contributedsignificantly to the educational value of the meeting.
 
 
"Our focus is on the industry rather than the academicaudience, but we set up great meetings and collaborations," said Reny Aniline,director of sales and marketing for Asuragen Inc. "Everyone in cancer is here."
 
 
"We're pleased with the amount of traffic to our booth,"said R&D Systems' key account manager, Jennifer Souvignier. "In fact, weran out of literature. It's not just people showing up to take papers; we'vehad a lot of good conversations about the science." 
 
This image is no longer availableThere was more in store for AACR meeting attendees duringthe early part of their week. On April 8, just outside the convention center,several thousand demonstrators rallied to call on the nation's policymakers toprioritize medical research funding. Officially dubbed the Rally for MedicalResearch, organized by the AACR, the rally's specific call to action was tospur Congress to spare the U.S. National Institutes of Health (NIH) from themandatory budget cuts brought about by the sequestration. The NIH lost $1.6billion in federal funding for medical research when sequestration cuts wentinto effect on March 1.
 
 
The AACR closed down its annual meeting to join nearly 200partnering organizations on the Carnegie Library grounds at Mt. Vernon Squarein downtown Washington. AACR meeting attendees were encouraged to participate;those who did were joined by cancer patients, physicians and advocates fromaround the country looking to voice their support of sustained investment inthe NIH's medical research. 
 
Speakers featured at the rally included RockefellerUniversity President Dr. Marc Tessier-Lavigne, AACR CEO Dr. Margaret Foti, U.S.Reps. Rosa DeLauro (D-Conn.) and Chris Van Hollen (D-Md.) and formerCongressman John Porter (R-Ill.), along with several survivors and patientadvocates. ABC News political analyst and National Public Radio (NPR) seniornews analyst Cokie Roberts served as the rally's emcee. 
 
"Listening to the patient advocates was really touching,"says Tabitha Bauman, a spokesperson for Rockland Immunochemicals. "They had amazingstories, which were probably the highlight of the whole event."
 
The AACR's Annual Meeting 2014 is scheduled for April 5-9,2014 in San Diego.
 
  
 
  
 
  
 
 
 
  
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue